Symbols

AORT

Artivion·NYSE

--(--)

AORT fundamentals

AORT Q4 2025 Earnings

Artivion (AORT) released its earnings on Feb 12, 2026: revenue was 115.99M (YoY +19.20%), missed estimates; EPS was 0.05 (YoY +112.82%), missed estimates.

Revenue / YoY

115.99M

+19.20%

EPS / YoY

0.05

+112.82%

Report date

Feb 12, 2026

AORT Earnings Call Summary for Q4,2025

Revenue Growth: 2025 adjusted EBITDA up 26%, with stent grafts (+36%) and On-X (+24%) leading the charge. 2026 guidance targets 10-14% revenue growth, driven by AMDS, On-X, and NEXUS PMA approvals.
Clinical Momentum: AMDS PMA on track for mid-2026, while NEXUS IDE trial data shows 94% survival in high-risk patients, positioning for U.S. market entry.
Strategic Investments: $50 million in 2026 CapEx to expand On-X capacity and advance R&D, supporting long-term EBITDA expansion目标.
Market Expansion: Japan AMDS entry contingent on U.S. PMA, while On-X cardiologist education programs aim to unlock $100 million U.S. market opportunity.

Earnings

EPS

Revenue

Revenue & Expenses

AORT has released its 2025 Q4 earnings report, with revenue of 115.99M, reflecting a YoY change of 19.20%, and net profit of 2.43M, showing a YoY change of 114.72%. The Sankey diagram below clearly presents AORT's revenue sources and cost distribution.

Key Indicators

Artivion (AORT) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Artivion (AORT)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Artivion (AORT)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Artivion (AORT)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown